Condition: Amyloidosis · AL Amyloidosis · Sponsor: K-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc.
This is a single arm, Open-Label, Phase 1/2 Study of ZN-d5 for the Treatment of Relapsed or Refractory Light Chain (AL) Amyloidosis.
This description comes directly from the study's public registry record.
Contact details are listed per location below or on the registry record.
Always discuss trial participation with your own doctor first.
| University of Southern California | Los Angeles, California, United States | — |
| Colorado Blood Cancer Institute | Denver, Colorado, United States | — |
| Tulane University | New Orleans, Louisiana, United States | — |
| Washington University | St Louis, Missouri, United States | — |
| Tennessee Oncology | Nashville, Tennessee, United States | — |
| Blackwater (Westmead) Hospital | Westmead, New South Wales, Australia | — |
| Princess Alexandra Hospital | Brisbane, Queensland, Australia | — |
| Royal Adelaide Hospital | Adelaide, South Australia, Australia | — |
| Sir Charles Gairdner Hospital | Nedlands, Western Australia, Australia | — |
| Bank of Cyprus Hospital | Nicosia, Cyprus | — |
| National and Kapodistrian University of Athens | Athens, Greece | — |
| Rambam Hospital | Haifa, Israel | — |
+ 9 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05199337